Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZMA 001

Next Previous
X
Search
Drug Profile

ZMA 001

Alternative Names: BC-NKA-20008; ZMA-001

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicinal Bioconvergence Research Center
  • Developer National Heart, Lung and Blood Institute; ZYMEDI
  • Class Monoclonal antibodies
  • Mechanism of Action Lysine tRNA ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 30 Jul 2024 ZMA 001 receives Orphan Drug status for Pulmonary arterial hypertension in USA
  • 06 Nov 2023 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in USA (IV) (NCT05967299)
  • 02 Jul 2023 ZYMEDI signs a clinical cooperative research and development agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI) to develop ZMA 001 for the treatment of pulmonary arterial hypertension

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top